Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Chipotle's High-Protein Push Targets GLP-1 Users, Analysts See Upside
01:04pm, Friday, 09'th Jan 2026
Chipotle Mexican Grill, Inc. (NYSE: CMG) shares are trading higher on Friday.
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
06:00pm, Thursday, 08'th Jan 2026
VANCOUVER, BC / ACCESS Newswire / January 8, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered
Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth
09:18am, Thursday, 08'th Jan 2026
Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical integratio
Omada Health's GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss
09:00am, Thursday, 08'th Jan 2026
SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of memb
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-
Warning: This Skyrocketing Stock Has a Hidden Risk
08:30pm, Tuesday, 06'th Jan 2026
Novo Nordisk was the first company to introduce a GLP-1 shot. Eli Lilly's GLP-1 shot quickly became the industry leader after its introduction.
Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?
06:00pm, Tuesday, 06'th Jan 2026
Novo Nordisk has released a pill version of its GLP-1 drug. In 2025, the company announced that it was ending a GLP-1 trial related to the drug's impact on Alzheimer's.
Novo Nordisk launches first oral GLP-1 weight loss pill in the US
11:40am, Monday, 05'th Jan 2026
Novo Nordisk (NYSE:NVO) has made its Wegovy pill, the first oral GLP-1 treatment for weight loss, broadly available to patients in the United States. The launch marks a new development in obesity trea
Is It Time to Dump Your Shares of Eli Lilly?
09:00am, Monday, 05'th Jan 2026
Novo Nordisk was the first company to introduce GLP-1 weight loss drugs. Eli Lilly's GLP-1 drugs have since taken the lead in the emerging weight loss space.
A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone A NovoCare® Recogniz
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
08:00am, Monday, 05'th Jan 2026
American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices of the drug, called the Wegovy p
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
08:00am, Monday, 05'th Jan 2026
Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose of
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
07:00am, Monday, 05'th Jan 2026
Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approxima
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
07:00am, Monday, 05'th Jan 2026
RHB-102 1 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis
- The P hase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with di
